New Prediction Feature for Hypoglycemia Now Available in Sugar.IQ(TM) Personal Diabetes Assistant App, Developed by Medtronic and IBM Watson Health
January 3, 2019
IQcast Feature Aims to Predict the Likelihood of a Low Glucose Event Up to Four Hours in Advance
DUBLIN and CAMBRIDGE, Mass. - January 3, 2019 - Medtronic plc (NYSE:MDT), the global leader in medical technology, services and solutions, and its strategic technology partner, IBM (NYSE:IBM) Watson Health, today announced a new feature for the Sugar.IQ(TM) personal diabetes assistant app called IQcast(TM). Using artificial intelligence (AI) technology from IBM Watson Health, the feature aims to predict the likelihood of an individual experiencing a low glucose event within an upcoming 1-4 hour window.
Medtronic to Acquire Nutrino Health
November 21, 2018
(GLOBE NEWSWIRE via COMTEX) --Acquisition to Augment Diabetes Capabilities with Nutritional Database and Data Science
DUBLIN and TEL AVIV, Israel - November 21, 2018 - Medtronic plc (NYSE:MDT), a global leader in medical technology, and Nutrino Health Ltd., a leading provider of nutrition-related data services, analytics, and technologies, today announced the companies have entered into a definitive agreement under which Medtronic will acquire Nutrino. Given that food and nutrition are central components in effective diabetes management, the companies recognized an opportunity to improve clinical outcomes for people with diabetes by integrating Nutrino's extensive food analysis infrastructure, nutrition science expertise and artificial intelligence (AI)-driven personalized insights with Medtronic's technology and future innovations.
Medtronic Launches Patient Engagement Program That Leverages Gamification to Help Motivate and Engage Patients Living with Diabetes
August 9, 2018
(GLOBE NEWSWIRE via COMTEX) --DUBLIN - August 9, 2018 - Medtronic today announced the official U.S. launch of the Medtronic Inner CircleSM patient engagement program, which uses gamification - the application of game design elements - to motivate and encourage people living with diabetes to achieve better health outcomes.
Medtronic Launches the MiniMed(TM) 670G System Performance Guarantee for Payers and Employers
June 28, 2018
(GLOBE NEWSWIRE via COMTEX) --DUBLIN- June 28, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the launch of the MiniMed(TM) 670G Performance Guarantee Program - an outcomes-based offering for payers and employers designed to mitigate costs for diabetes-related complications. With this Guarantee, Medtronic will provide flat-fee reimbursements up to $25,000 per pump over 4 years for qualifying diabetes-related inpatient hospitalization and emergency room admissions for eligible in-network patients in the United States.
Medtronic Receives CE Mark for MiniMed(TM) 670G Hybrid Closed Loop System
June 25, 2018
(GLOBE NEWSWIRE via COMTEX) --DUBLIN - June 25, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received CE (Conformité Européenne) Mark for the MiniMed(TM) 670G hybrid closed loop system - the first and only system to automate and personalize the delivery of basal insulin 24 hours a day1. The system is CE Mark approved for the treatment of people with type 1 diabetes 7 years of age and older with ongoing studies to expand the indication to additional patient populations.
MiniMed 670G System Real-World Data Show Improved Time in Range and Reduced Lows and Highs Across All Patient Groups Including a 41 Percent Time in Range Improvement for Previous MDI Patients
June 24, 2018
(GLOBE NEWSWIRE via COMTEX) --DUBLIN - June 24, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced real-world clinical outcomes for 32,178 users of the MiniMed(TM) 670G system. Data on more than 2 million patient days showed an average Time in Range of 70.6 percent across all age groups for those using the system's most advanced SmartGuard(TM) technology - the only smart algorithm that can adapt to fluctuating glucose levels and automatically self-adjust background insulin delivery. This advanced algorithm mimics some of the functions of a healthy pancreas and is the only technology in the world that proactively drives increased Time in Range - addressing both highs and lows.
Artificial Intelligence-Powered Sugar.IQ(TM) Diabetes Management App Developed by Medtronic and IBM Watson Health Now Commercially Available
June 22, 2018
Medtronic plc (NYSE:MDT), the global leader in medical technology, services and solutions, and its strategic technology partner, IBM (NYSE:IBM) Watson Health, today announced commercial availability of the Sugar.IQ(TM) smart diabetes assistant, a first-of-its-kind intelligent app designed to simplify and improve daily diabetes management. Approximately 30.3 million Americans have been diagnosed with diabetes, with 1.5 million new cases being diagnosed every year.1 More than 6 million of those impacted use insulin to manage their diabetes.2 People with diabetes face many daily challenges - managing their condition, understanding medical advice, knowing what to eat and when, the impact of food and activity on sugar levels, and trying to avoid critical glycemic events. The groundbreaking Sugar.IQ smart diabetes assistant leverages artificial intelligence (AI) and analytic technologies from IBM Watson Health to continually analyze how an individual's glucose level responds to their food intake, insulin dosages, daily routines, and other factors, such as information provided by the app user.
Medtronic Receives FDA Approval of New Pediatric Indication for the MiniMed(TM) 670G Hybrid Closed Loop System in Children Ages 7-13
June 21, 2018
(GLOBE NEWSWIRE via COMTEX) - June 21, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that the U.S. Food and Drug Administration (FDA) has approved the use of the MiniMed(TM) 670G system in patients with type 1 diabetes seven years of age and older. This newest system by Medtronic features the company's most advanced SmartGuard(TM) technology and most accurate CGM - the Guardian Sensor 3 - which work together to automate the delivery of a personalized amount of basal insulin every five minutes based on sensor glucose values. The system constantly self-adjusts to help avoid highs and lows, allowing patients to spend more Time in Range (the percentage of time spent in the optimal glycemic range of 70-180 mg/dL).
Medtronic Introduces Updated iPro(TM)2 myLog App with FoodPrint(TM) Report Enhancing Diagnostic CGM for People with Diabetes
June 19, 2018
DUBLIN - June 19, 2018 - Medtronic (NYSE:MDT), the global leader in medical technology, today announced the availability of the updated iPro(TM)2 myLog app with FoodPrint(TM) Report. The iPro2 myLog app offers a simple way for clinics to import patients' logged data during their professional iPro2 continuous glucose monitoring (CGM) evaluation. With the addition of the FoodPrint report, patients' meals are graded based on their body's unique glucose reaction, making it easy for them to understand the link between meals and glucose variability.
Medtronic Receives FDA Approval for Guardian Connect Continuous Glucose Monitoring (CGM) System for People Living with Diabetes
March 12, 2018
Medtronic plc (NYSE:MDT), the global leader in medical technology, services and solutions, today announced it received U.S. Food and Drug Administration (FDA) approval for its Guardian(TM) Connect continuous glucose monitoring (CGM) system, for people with diabetes ages 14 to 75 years. The Guardian Connect system is the first smart standalone CGM system1 to help people with diabetes stay ahead of high and low glucose events. The Guardian Connect system empowers people using multiple daily injections (MDI) to more proactively manage their diabetes.
Medtronic Receives FDA Approval for New Arm Indication for Guardian(TM) Sensor 3 - Further Enhancing the MiniMed(TM) 670G Hybrid Closed Loop Experience
February 26, 2018
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that the U.S. Food and Drug Administration (FDA) has approved a new arm indication for the Guardian(TM) Sensor 3. This expanded indication will enable patients to wear the sensor on the upper arm - delivering more flexibility and enhanced performance for users, as well as improved accuracy, with a MARD of 8.7 percent following typical calibration methods used with the MiniMed(TM) 670G system. The Guardian Sensor 3 is Medtronic's newest and most accurate CGM to-date and is the only sensor FDA approved to control automated insulin delivery via a hybrid closed loop system - the MiniMed 670G system.
Medtronic Introduces MiniMed(TM) Mio(TM) Advance Infusion Set for People with Diabetes
February 21, 2018
Medtronic plc (NYSE:MDT), the global leader in medical technology, services and solutions, today introduced the MiniMed(TM) Mio(TM) Advance infusion set. The MiniMed Mio Advance infusion set is the newest addition to the MiniMed portfolio of infusion sets and gives patients a simpler, faster and more convenient set change with fewer steps1,2. The new infusion set will first be available in select countries around the world with plans to expand availability over time.
Medtronic Announces Upcoming Data Presentations at the Advanced Technologies and Treatments for Diabetes 11th International Conference
February 13, 2018
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced its schedule of notable sessions that will be presented at the Advanced Technologies & Treatments for Diabetes (ATTD) 11th International Conference in Vienna, Austria, from February 14-17. A significant portion of the scientific data being presented focuses on the company's insulin pump systems, including new data on the benefits of the latest SmartGuard(TM) technology that drives the MiniMed(TM) 670G system1 in children with type 1 diabetes. Medtronic will also host an exclusive symposium titled "Using Technology to Increase Time in Range: The New Goal for Glycemic Control" on Thursday, February 15, from 10:30-12:00 CET.
Medtronic Announces First Economic Analysis Demonstrating Benefits of Professional CGM in People with Type 2 Diabetes
October 25, 2017
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced data from the first economic analysis conducted on the use of professional continuous glucose monitoring (CGM) in people with type 2 diabetes. Data from the study demonstrated significant cost avoidance to the healthcare system when used during a therapy change or when used at least twice per year. The results also reinforced the well-established clinical benefits of professional CGM use in people with type 2 diabetes. The study, published in the Journal of Medical Economics, retrospectively analyzed real-world data of over 5,600 people who used professional CGM in the United States using health insurance medical and pharmacy claims, enrollment data and laboratory data.
Medtronic Announces Voluntary Recall of Diabetes Infusion Sets
September 11, 2017
Medtronic plc (NYSE:MDT) announced today that it has started to inform patients worldwide of a voluntary recall of specific lots of infusion sets used with all models of Medtronic insulin pumps. The recall is related to a certain discontinued component in these infusion sets and does not include insulin pumps or glucose sensors.
Medtronic Announces Outcomes-Based Agreement with Aetna for Type 1 and Type 2 Diabetes Patients
June 26, 2017
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced a new outcomes-based agreement with Aetna (NYSE:AET) for type 1 and type 2 diabetes patients currently on multiple daily insulin injections for their diabetes management. The agreement will measure health outcomes for those patients that choose to transition to pump therapy using a Medtronic insulin pump featuring SmartGuard(TM) Technology, including the new MiniMed(TM) 670G system* - the first and only system that constantly self-adjusts to keep patients' blood sugar levels in range based on their personalized needs.1
Medtronic Initiates U.S. Launch of World's First Hybrid Closed Loop System for Type 1 Diabetes
June 7, 2017
The MiniMed(TM) 670G System Features the Company's Most Advanced SmartGuard(TM)HCL Technology and New Guardian(TM) Sensor 3 Medtronic plc (NYSE:MDT), today announced the U.S. launch of the MiniMed(TM) 670G system - the world's first Hybrid Closed Loop system for people with type 1 diabetes. Featuring the company's most advanced SmartGuard(TM) HCL technology and Guardian(TM) Sensor 3, it is the only insulin pump approved by the Food and Drug Administration (FDA) that enables personalized and automated delivery of basal insulin, the background insulin needed to maintain stable blood sugar levels throughout the day and night. The advanced SmartGuard HCL algorithm works in conjunction with the company's most accurate sensor to date - Guardian Sensor 3 - to self-adjust basal insulin delivery every five minutes based on real-time needs. Through this personalized design, the system is able to maximize Time in Range - the amount of time sugar levels stay within a range considered healthy by clinical standards. The system also exclusively features the CONTOUR®NEXT LINK 2.4 blood glucose monitoring system (BGMS) from Ascensia Diabetes Care.
Medtronic Announces Scientific Data Presentations at the American Diabetes Association 77th Meeting
June 6, 2017
Medtronic (NYSE:MDT), the global leader in medical technology, today announced its schedule of notable sessions that will be presented at the 77th Scientific Sessions of the American Diabetes Association, in San Diego, June 9-13. A significant portion of the scientific data being presented focuses on Medtronic's insulin pump systems, including the MiniMed(TM) 670G system, the world's first hybrid closed-loop system which will be commercially available this month. Data will also be presented on the Sugar.IQ(TM) app, powered by IBM Watson technology, as well as managing glucose control for patients at Diabeter clinics in the Netherlands.
Medtronic EVP & President Hooman Hakami to Speak at Oppenheimer Healthcare Conference
March 16, 2017
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will participate in the Oppenheimer 27th Annual Healthcare Conference on Tuesday, March 21, 2017, in New York City. Hooman Hakami, executive vice president and group president of Medtronic's Diabetes Group, will answer questions about the company beginning at 8:35 a.m. EDT (7:35 a.m. CDT).
Medtronic and Fitbit Partner to Integrate Health and Activity Data Into New CGM Solution for Simplified Type 2 Diabetes Management
Dec. 7, 2016
New iPro(TM)2 myLog App Collects Data from Continuous Glucose Monitors (CGM) and Fitbit Activity Trackers, Provides Meaningful Insights on How Exercise Impacts Glucose Levels. Medtronic plc (NYSE: MDT), the global leader in medical technology, and Fitbit (NYSE: FIT), the leader in the connected health and fitness market, announced a partnership to integrate health and activity tracking for patients living with diabetes and their physicians and care teams. The iPro™2 myLog mobile app will allow patients living with type 2 diabetes to see their glucose levels and physical activity data in one streamlined application. The new integration and partnership brings together Medtronic's sophisticated medical technology with the convenience of automatic activity tracking from Fitbit, which provides meaningful insights into how exercise impacts glucose levels for more effective diabetes care management.
Medtronic EVP & President Hooman Hakami to Speak at Jefferies Diabetes Technology Summit
Dec. 8, 2016
DUBLIN - Dec. 8, 2016 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will participate in the Jefferies 2016 Diabetes Technology Summit on Monday, December 12, 2016, in New York City. Hooman Hakami, executive vice president and group president of Medtronic's Diabetes Group, will make a presentation and answer questions about the company beginning at 1:00 p.m. EST (12:00 p.m. CST).
Medtronic Receives FDA Approval for World's First Hybrid Closed Loop System for People with Type 1 Diabetes
Sept. 28, 2016
DUBLIN - Sept. 28, 2016 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval of its MiniMed® 670G system - the first Hybrid Closed Loop insulin delivery system approved anywhere in the world. Featuring the company's most advanced algorithm - SmartGuard(TM) HCL - the system is the latest innovation in Medtronic's phased approach toward developing a fully automated, closed loop system. Medtronic is committed to simplifying and improving diabetes management through the advancement of smart algorithms that achieve greater glucose control with reduced patient input. Through SmartGuard HCL, the system builds on Medtronic's industry leading algorithms to offer therapy customization so patients and providers can choose from increasing levels of automation that best fit their diabetes management needs.
Medtronic Announces First Live Experience of Sugar.IQ with Watson for People Living with Diabetes c
Sept. 27, 2016
DUBLIN and SANTA CLARA, Calif. - Sept. 27, 2016 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that Sugar.IQ with Watson, the first-of-its-kind cognitive app that helps detect important patterns and trends for people with diabetes, is now in live use for the first time. With app development now completed, the first users are participating in real-world testing of the final release candidate. Developed with IBM Watson Health, the Sugar.IQ app will be demonstrated at the 10th Annual Health 2.0 Fall Conference in Santa Clara, Calif. The Sugar.IQ app uses real-time continuous glucose monitoring (CGM) and insulin information from Medtronic pumps and glucose sensors. It leverages IBM cognitive computing power, combined with Medtronic's expertise in diabetes, to find hidden patterns in diabetes data and will offer real-time and personalized insights so that people with diabetes can spend less time worrying about their data and have more freedom to simply enjoy life. The app will provide individualized guidance in understanding and helping to manage elements of daily diabetes decisions by creating a single platform that brings together relevant data and provides context and insights.
Medtronic Announces U.S. Launch of the MiniMed® 630G System with New User-Friendly Insulin Pump Design and SmartGuard(TM) Technology
Aug 11, 2016
DUBLIN - August 11, 2016 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the U.S. commercial launch of its MiniMed 630G system with SmartGuard technology FDA approved for the treatment of people with diabetes mellitus sixteen years of age and older. The MiniMed 630G features a new insulin pump hardware platform and new user-friendly design that combines personalized diabetes management with industry-leading clinical performance. The MiniMed 630G system is the newest member of the MiniMed family-the most prescribed integrated insulin delivery system brand in the world.
Medtronic Converts 125 Million Patient Days of Data Into Personalized Insights That Improve Diabetes Management
June 10, 2016
DUBLIN and NEW ORLEANS - June 10, 2016 - Delivering on its vision to transform care for the millions currently living with diabetes through intelligent data, Medtronic plc (NYSE:MDT) announced new product developments and technology partnerships at the American Diabetes Association (ADA) 76th Scientific Sessions that will create meaningful insights for providers and people with diabetes.
Medtronic and Qualcomm Collaborate to Aim to Improve Care and Health Outcomes for People with Type 2 Diabetes
May 25, 2016
Dublin and San Diego – May 25, 2016 - Medtronic plc (NYSE:MDT) and Qualcomm Incorporated (NASDAQ:QCOM) through its wholly-owned subsidiary, Qualcomm Life, Inc., today announced a global, multi-year collaboration to jointly develop future generation continuous glucose monitoring (CGM) systems that aim to improve health outcomes for people with diabetes. By giving insights to doctors and people with type 2 diabetes concerning glucose levels, the companies intend to enable more informed care, especially for those who do not have control of their diabetes today. The collaboration seeks to leverage Medtronic's market-leadership in diabetes management and Qualcomm Life's expertise in developing reference designs for wireless, single-use and small integrated modules to create more affordable, easier-to-use CGM systems, including a new sensor and smaller design that can provide near real-time and retrospective glucose data.
New Data Shows Benefits of Medtronic Insulin Pumps for People with Type 2 Diabetes
April 13, 2016
Dublin – April 13, 2016 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the publication of new data in Diabetes, Obesity and Metabolism from the continuation phase of the OpT2mise study, providing further clinical evidence in support of insulin pumps for people with insulin-requiring type 2 diabetes. The OpT2mise study is the largest randomized controlled trial to compare the efficacy and safety of insulin pump therapy versus multiple daily injections (MDI) for poorly controlled type 2 patients.
Medtronic Named One of the World’s Most Admired Companies
February 19, 2016
Dublin - February 19, 2016 - Fortune magazine announced today that Medtronic is included on its list of the World's Most Admired Companies for 2016. The list is considered one of the leading measures of corporate reputation among the world’s largest companies. Medtronic is ranked second in the Medical Products and Equipment category.
Medtronic's iPro(TM)2 Professional CGM Shows Benefits for People with Type 2 Diabetes
February 5, 2016
MILAN - February 5, 2016 - A retrospective analysis of the iPro2 Professional CGM from Medtronic plc (NYSE:MDT), the global leader in medical technology, demonstrates that patients with type 2 diabetes experience high rates of glycemic variability, hypoglycemia and hyperglycemia regardless of whether they manage their diabetes with diet/exercise, oral medication or insulin. Using this actionable iPro2 Professional CGM information, physicians can make therapy adjustments, recommendations and educational decisions for their patients to help improve glucose control. The results of the analysis were featured in an oral presentation at the 9th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2016).
Medtronic and Chengdu Sign Insulin Pump Manufacturing Agreement
January 11, 2016
DUBLIN and CHENGDU, China - January 11, 2016 - Medtronic plc (NYSE:MDT), the global leader in medical technology, has formed a partnership with the Chengdu municipal government to manufacture and deploy advanced diabetes therapies in Chengdu, China.
CES Puts IBM and MDT In Spotlight - Partners Unveil Plans For Cognitive Diabetes App
January 7, 2016
Las Vegas, NV – January 7, 2016 - IBM CEO Ginni Rometty and Medtronic CEO Omar Ishrak took center stage during a keynote address at the 2016 Consumer Electronics Show (CES) in Las Vegas to unveil the latest advances in applying cognitive computing to diabetes management.
Medtronic Expands Access to Type 2 Diabetes Products with Selection of Henry Schein as Exclusive Distributor
December 2, 2015
DUBLIN and MELVILLE, N.Y. - December 2, 2015 - Medtronic plc (NYSE:MDT), the global leader in medical technology, has selected Henry Schein Medical, the U.S. Medical business of Henry Schein, Inc. (NASDAQ: HSIC), as an exclusive distributor of selected diabetes products to primary care physicians (PCPs) in the U.S. The exclusive distribution agreement broadens access to Medtronic solutions for people with type 2 diabetes under the care of primary care physicians who oversee their diabetes management. Henry Schein Medical is a leading provider of health care products and services to office-based medical practitioners in the U.S.
Medtronic Enhances Utility of Professional Continuous Glucose Monitor (CGM) by Launching Pattern Snapshot for iPro®2 Professional CGM
November 30, 2015
DUBLIN - November 30, 2015 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the availability of a new CareLink® iPro report called Pattern Snapshot for iPro2 Professional CGM system. The new one-page report provides a health care professional (HCP) with information for quick interpretation of detailed glucose data over time. The identified patterns are based on advanced algorithms that automatically identify an individual's top glucose control issues and their possible causes. The report information and visuals also serve as a teaching tool to help educate people with diabetes about their own glucose profile.
Latest Cardiac and Diabetes Advancements from Medtronic Win 2015 'Best of What's New' Awards from Popular Science
November 18, 2015
DUBLIN - November 18, 2015 - Medtronic plc (NYSE: MDT) today announced that its Micra® Transcatheter Pacing System (TPS) and Hybrid Closed Loop system have both earned the 2015 'Best of What's New' award in the health category by Popular Science, the world's largest science and technology magazine.
MiniMed Connect Now Available from Medtronic for Smartphone Access to Personal Diabetes Data
September 28, 2015
DUBLIN - September 28, 2015 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced U.S. commercial availability of MiniMed Connect, the first and only product to enable people with diabetes to discreetly and conveniently view their insulin pump and continuous glucose monitoring (CGM) information on a smartphone.
BD and Medtronic Collaborate to Introduce a New Infusion Set with BD FlowSmart(TM) Technology Designed to Improve Insulin Pump Therapy
June 8, 2015
BOSTON, MA - JUNE 8, 2015 - BD Medical, a segment of leading global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX), and Medtronic plc (NYSE: MDT) today announced a collaboration to introduce a new insulin pump infusion set with BD FlowSmart(TM) technology. An insulin infusion set delivers insulin from the pump to the body and is a critical part of the overall pump system.
Medtronic Receives FDA Clearance of MiniMed® Connect for More Convenient Access to Personal Diabetes Data
June 5, 2015
BOSTON - June 5, 2015 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced U.S. Food and Drug Administration (FDA) clearance of MiniMed® Connect. Designed to provide a mobile connection to critical information for managing diabetes, MiniMed Connect is the first product to enable people with diabetes to discreetly and conveniently view their insulin pump and continuous glucose monitor (CGM) data on a smartphone and provides remote monitoring and text message notifications for their loved ones.
Medtronic and Samsung Partner to Enhance Diabetes Management and Empower Overall Patient Health
June 5, 2015
BOSTON - June 5, 2015 - Medtronic plc (NYSE:MDT), the global leader in medical technology, and Samsung Electronics, a world leader in consumer electronics committed to transformative mobile health and wellness solutions, today announced a partnership to improve diabetes management for the millions of people at risk and currently living with the disease.
Medtronic Expands Access to Diabetes Device Data Through Agreement with Glooko
June 5, 2015
BOSTON - June 5, 2015 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced an agreement with Glooko, the trusted leader in diabetes data unification and analytics, to improve access to meaningful diabetes health data in a safe and secure way.
IBM and Medtronic to Partner to Improve Diabetes Care
April 13, 2015
ARMONK, NY and DUBLIN - April 13, 2015 - IBM (NYSE: IBM) and Medtronic (NYSE: MDT) today announced that they will work together to combine powerful analytics and cognitive computing with diabetes medical devices and health data to develop a new generation of personalized diabetes management solutions.
Medtronic Acquires Diabeter, Innovative Diabetes Care Provider
April 2, 2015
DUBLIN - April 2, 2015 - Medtronic plc (NYSE:MDT) today announced its acquisition of Diabeter, an innovative, independent Netherlands-based diabetes clinic and research center dedicated to providing comprehensive and individualized care for children and young adults with diabetes.
Diabetes Technology & Therapeutics Publishes Retrospective Analysis Detailing Impact of Threshold Suspend in Addressing Hypoglycemia
February 12, 2015
DUBLIN - February 12, 2015 - Medtronic plc (NYSE:MDT) today announced results of a retrospective analysis based on real-world data from over 20,000 MiniMed® 530G users, which found that the pump's Threshold Suspend feature reduced hypoglycemia, especially at night, without significantly increasing hyperglycemia.
Medtronic Completes Acquisition of Covidien
January 26, 2015
DUBLIN, Ireland –Medtronic plc (NYSE: MDT), a global leader in medical technology, services and solutions, announced today that it has successfully completed the previously announced acquisition of Covidien plc (NYSE: COV). Under the terms of the acquisition agreement, Medtronic, Inc. and Covidien plc are now combined under Medtronic plc. Shares of Medtronic plc are expected to begin trading on the New York Stock Exchange (NYSE) under the symbol “MDT” on Tuesday, January 27, 2015.
Medtronic Issues $250,000 in Health Access Grants to Support Diabetes Services for the Underserved of San Antonio
December 8, 2014
SAN ANTONIO, TX - December 8, 2014 - Medtronic, Inc. (NYSE: MDT) today announced that five San Antonio community organizations will receive a combined $250,000 in Health Access Grants in recognition of their continued commitment to promoting healthy lifestyles and improving access to healthcare, with an emphasis on diabetes. As Medtronic marks the five year anniversary of its San Antonio location, this announcement demonstrates the company's ongoing support of the local community. Medtronic Philanthropy awards Health Access Grants in 36 communities around the world where Medtronic has a major presence.
Medtronic Begins Pivotal Study of First Predictive Low Glucose Management Technology for People with Diabetes
October 4, 2014
MINNEAPOLIS – October 4, 2014 - Medtronic, Inc. (NYSE:MDT) today announced that the first patients have been enrolled in an investigational device exemption (IDE) study of its breakthrough Predictive Low Glucose Management (PLGM) technology, marking a critical step toward development of an artificial pancreas in the U.S. market. The trial will evaluate the safety of its next-generation integrated insulin pump and continuous glucose monitoring (CGM) system, which automatically stops insulin delivery when the sensor measures a glucose level predicted to approach the lowest tolerable limit, and then resumes insulin delivery after those glucose levels recover. The technology is designed to help people with diabetes better manage the challenges of hypoglycemia (low blood sugar) and rebound hyperglycemia (high blood sugar) inherent in external insulin therapy use.
People with Type 2 Diabetes Achieve Superior Outcomes with Insulin Pumps vs. Multiple Daily Injections
July 2, 2014
MINNEAPOLIS - July 2, 2014 - As an example of its commitment to improving clinical outcomes for all people with diabetes, Medtronic, Inc. (NYSE:MDT) today announced the results of the OpT2mise trial, which showed that MiniMed insulin pumps safely achieve better glucose control for people with insulin-requiring type 2 diabetes than multiple daily injections. While the benefits of insulin pump therapy for people with type 1 diabetes are well proven, this is the largest global study to evaluate the comparative efficacy of insulin pump therapy versus multiple daily insulin injections in people with type 2 diabetes with poor glycemic control. Study results were published online in The Lancet today.
Medtronic Applauds AACE/ACE on Their Updated Insulin Pump Therapy Consensus Statement
May 19, 2014
MINNEAPOLIS - May 19, 2014 - Medtronic, Inc. (NYSE:MDT) applauds the American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE) on their updated consensus statement on insulin pump therapy. In addition to continued support of insulin pump therapy for people with type 1 diabetes, AACE and ACE recognize the clinical value of insulin pumps in improving glucose control for those with intensively managed insulin-dependent type 2 diabetes. Improving glucose control is the key to helping people with diabetes avoid dangerous complications so that they can live fuller, healthier lives. The support of prestigious physician organizations helps ensure access to these therapies for people who need them.
Medtronic Names Hooman Hakami Executive Vice President and Group President of the Medtronic Diabetes Group
May 13, 2014
MINNEAPOLIS - May 13, 2014 - Medtronic, Inc. (NYSE: MDT) today announced the selection of Hooman Hakami as executive vice president and group president of the Medtronic Diabetes Group, the global leader in insulin pumps and continuous glucose monitoring systems. In this role, Hakami will lead Medtronic's entire global diabetes franchise, including research and development, operations, and sales and marketing.
Aetna and Medtronic Collaborate to Help Members Take Better Control of Type 2 Diabetes
March 3, 2014
HARTFORD, Conn. and MINNEAPOLIS, March 3, 2014 - Beginning this month, Aetna (NYSE: AET) and Medtronic, Inc. (NYSE: MDT) will work with doctors in a new program to reach up to 300 fully insured members with uncontrolled type 2 diabetes who may improve their health using insulin pump therapy. Eligible members will receive targeted education, case management and other patient support to help control blood sugar, which also may lower their health care costs. Information gathered from the program also is expected to help doctors and other health care providers more easily identify and support those who can benefit most from this therapy.
Medtronic Begins Distribution of i-port Advance® Injection Port Device for People with Diabetes
February 13, 2014
MINNEAPOLIS - February 13, 2014 - Medtronic, Inc. (NYSE:MDT) has begun distribution of i-port Advance® as part of a continued focus to provide meaningful therapy management solutions for people with diabetes. i-port Advance® can be used for people on insulin injection therapy who want to administer insulin conveniently while eliminating the need to puncture the skin with each dose of medication. i-port Advance® injection port is cleared by the FDA and indicated for patients who administer multiple daily subcutaneous injections of physician prescribed medications, including insulin.
Medtronic Issues $500,000 in Health Access Grants to Support Diabetes Services for the Underserved of Greater Los Angeles
December 4, 2013
NORTHRIDGE, CA - December 4, 2013 - The Diabetes business of Medtronic, Inc. (NYSE: MDT) today announced that eight community organizations will receive two-year Health Access Grants from Medtronic Philanthropy, totaling $500,000, in recognition of their continued commitment to improve access to Los Angeles-area healthcare services for underserved populations, with an emphasis on diabetes. Health Access Grants are awarded in 34 communities around the world where Medtronic has a major presence.
Medtronic, Lilly Diabetes Join Together as First Ever National Presenting Sponsors of the JDRF Walk To Cure Diabetes
November 1, 2013
MINNEAPOLIS, NEW YORK, and INDIANAPOLIS - Medtronic and Lilly Diabetes announced today that they will serve as national presenting sponsors of this season's JDRF Walk to Cure Diabetes. As the national presenting sponsors, Medtronic and Lilly will host educational booths at select local events and will work with their employees to form Walk teams at each location. The sponsorship, a first for JDRF and the Medtronic-Lilly Alliance, will help JDRF fund more than half a million dollars for type 1 diabetes (T1D) research.
Medtronic Gains Approval of First Artificial Pancreas Device System with Threshold Suspend Automation
September 27, 2013
MINNEAPOLIS - September 27, 2013 - Medtronic, Inc. (NYSE:MDT) today announced the U.S. Food and Drug Administration (FDA) approval of the MiniMed® 530G with Enlite®, a breakthrough, first-generation artificial pancreas system with Threshold Suspend automation for people with diabetes. Medtronic's system is the first in the United States that can automatically stop insulin delivery when sensor glucose values reach a preset level and when the patient doesn't respond to the Threshold Suspend alarm. The MiniMed 530G system incorporates the new Enlite sensor, Medtronic's most accurate and comfortable continuous glucose sensor with a 31 percent improvement in overall accuracy from the previous generation.
Medtronic Begins Overnight Artificial Pancreas Study
June 24, 2013
MINNEAPOLIS - June 24, 2013 - Medtronic, Inc. (NYSE:MDT) today announced the first patient enrollments in the U.S. Overnight Closed Loop Study, a key feasibility trial to begin the commercialization path for a third-generation, fully automated artificial pancreas system for people with diabetes. Under an investigational device exemption granted by the U.S. Food and Drug Administration, the study will examine a closed loop algorithm that is designed to automatically achieve a specified target glucose value throughout the night. The in-clinic study will also test Medtronic's breakthrough fault detection technology, which will be critical to the commercialization of a safe and effective system.
Medtronic Partners with National Institute of Hospital Administration in China to Develop Diabetes Care Pathway
May 1, 2013
MINNEAPOLIS - May 1, 2013 - Medtronic, Inc. (NYSE: MDT) announced today it has entered into an innovative partnership with the National Institute of Hospital Administration, an important think tank under China's National Health and Family Planning Commission, to carry out a series of research projects focusing on building an integrated care pathway for patients with Type 1 diabetes. This effort is an example of a partnership focused on working with an important organization to access data that can be used to understand the economic and clinical value of therapies and how they can be best utilized in a patient population.
STAR 3 Trial Results Confirm Medtronic's Sensor-Augmented Insulin Pump Therapy Achieves Better Glucose Control Than Daily Insulin Injections in People with Diabetes
June 29, 2010
MINNEAPOLIS – June 29, 2010 - In the longest and largest randomized, controlled study of sensor-augmented insulin pump therapy in type 1 diabetes, adult and pediatric patients using the Medtronic MiniMed Paradigm® REAL-Time System achieved better glucose control without an increase in hypoglycemia compared to multiple daily insulin injections (MDI), the most common approach to care today.
For more announcements and information, please visit the Medtronic Newsroom
For media inquiries pertaining to the Diabetes Group of Medtronic, please contact:
For all other media inquiries please select the appropriate Global Public and Media Relations contact